Aigen Investment Management’s NovoCure NVCR Stock Holding History

Aigen Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,209	Closed	-$191K	–	921
2024 Q3	$191K	Sell	12,209 -22,980	-65%	-$417K	0.04%	594
2024 Q2	$603K	Buy	35,189 +24,312	+224%	+$428K	0.12%	249
2024 Q1	$170K	Buy	+10,877	New	+$160K	0.04%	566
2023 Q4	–	Sell	-45,433	Closed	-$734K	–	987
2023 Q3	$734K	Buy	+45,433	New	+$1.31M	0.14%	242
2021 Q4	–	Sell	-5,259	Closed	-$611K	–	1139
2021 Q3	$611K	Buy	+5,259	New	+$795K	0.12%	218
2021 Q2	–	Sell	-1,690	Closed	-$223K	–	652
2021 Q1	$223K	Buy	+1,690	New	+$267K	0.03%	513
2020 Q3	–	Sell	-19,774	Closed	-$1.17M	–	1032
2020 Q2	$1.17M	Buy	19,774 +6,999	+55%	+$460K	0.15%	210
2020 Q1	$860K	Sell	12,775 -9,616	-43%	-$760K	0.11%	253
2019 Q4	$1.89M	Buy	+22,391	New	+$1.81M	0.31%	72

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aigen Investment Management's NVCR Position: Q4 2024 in Review

Aigen Investment Management sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 12,209 shares — an estimated $191K sold.

Aigen Investment Management first reported a position in NVCR in Q4 2019 and held it in 9 quarters. The position peaked at $1.89M in Q4 2019. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

Aigen Investment Management reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
Aigen Investment Management sold 12,209 NovoCure shares in Q4 2024, an estimated $191K.
Aigen Investment Management first reported a position in NovoCure in Q4 2019 and held it in 9 quarters.
Aigen Investment Management's NovoCure position peaked at $1.89M in Q4 2019.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Aigen Investment Management's 13F filing for Q4 2024, filed 6 Feb 2025.